title: Establishing short-term prognosis in Frontotemporal Lobar Degeneration spectrum: role of genetic background and clinical phenotype.
abstract: BACKGROUND
  Establishing the short-term prognosis in Frontotemporal Lobar Degeneration (FTLD) is a clinical challenge for defining disease outcomes and monitoring therapeutic interventions. No reliable neuropsychological assessment balancing all FTLD aspects is available yet, thus no clear-cut follow-up study has been performed.
  
  
  OBJECTIVE
  To evaluate the rate of progression and the predictors of worsening in FTLD patients.
  
  
  METHODS
  One-hundred twenty-seven FTLD patients entered the study and were re-evaluated at 1-year follow-up. A statistical driven approach on wide neuropsychological, behavioral, and functional data was applied to identify homogeneous groups both at baseline and at follow-up within FTLD. Three set of predictors on disease progression were considered: (i) the demographic characteristics, (ii) the genetic background, i.e. Apolipoprotein E (APOE) genotype, Tau haplotype, and functional polymorphisms affecting serotonin and dopamine pathways, and (iii) the clinical phenotype.
  
  
  RESULTS
  Among FTLD, two groups of patients were recognized on the basis of the overall assessment, thus termed for different disease severity as "good performers" and "bad performers". At 1-year follow-up, almost 30% of FTLD patients progressed from "good" to "bad" performances, whilst 70% maintained stable "good" performances. APOE varepsilon4 allele, Tau H2 haplotype and behavioral variant FTD phenotype were associated with worse prognosis over time.
  
  
  CONCLUSIONS
  This preliminary study proposed genetic and clinical predictors in FTLD progression. The identification of disease-modifying predictors of prognosis opens a new avenue in studying FTLD, and may contribute to define outcomes and to monitor pharmacological targets.
authors.affiliation: Centre for Aging Brain and Dementia, Department of Neurology, University of Brescia, 1-25100 Brescia, Italy. bborroni@inwind.it
authors.forename: Barbara
authors.initials: B
authors.lastname: Borroni
authors.forename: Mario
authors.initials: M
authors.lastname: Grassi
authors.forename: Chiara
authors.initials: C
authors.lastname: Agosti
authors.forename: Enrico
authors.initials: E
authors.lastname: Premi
authors.forename: Silvana
authors.initials: S
authors.lastname: Archetti
authors.forename: Antonella
authors.initials: A
authors.lastname: Alberici
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Bellelli
authors.forename: Luigi
authors.initials: L
authors.lastname: Caimi
authors.forename: Monica
authors.initials: M
authors.lastname: Di Luca
authors.forename: Alessandro
authors.initials: A
authors.lastname: Padovani
mesh_terms: D000368:Aged; D053327:Apolipoprotein E4 / Q000235:genetics; D002394:Catechol O-Methyltransferase / Q000235:genetics; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D057174:Frontotemporal Lobar Degeneration / Q000175:diagnosis* / Q000235:genetics* / Q000628:therapy; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D010641:Phenotype; D011379:Prognosis; D012307:Risk Factors; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics; D013997:Time Factors; D016875:tau Proteins / Q000235:genetics
chemical_list: D053327:Apolipoprotein E4; C054369:MAPT protein, human; C493230:SLC6A4 protein, human; D050486:Serotonin Plasma Membrane Transport Proteins; D016875:tau Proteins; D002394:Catechol O-Methyltransferase